• BioMarin Pharmaceutical average return on tangible equity for 2023 was 2.89, a 39.61% increase from 2022.
• BioMarin Pharmaceutical average return on tangible equity for 2022 was 2.07, a 82.09% increase from 2021.
• BioMarin Pharmaceutical average return on tangible equity for 2021 was 11.56, a 32.36% decline from 2020.

Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.